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Summary
Objective: To determine the causative organisms and characteristics of patients presenting with
meningitis in Bangui in order to provide guidance to physicians for case management.
Methods: Adults with proven or suspected meningitis were enrolled in this prospective study.
Laboratory tests: Full blood count, blood chemistry, and HIV tests were performed. Cerebrosp-
inal fluid (CSF) was submitted for routine microbiology, chemistry (glucose, protein), and
hematology testing. When classical microbiology analyses were negative, a broad-range bacterial
polymerase chain reaction (BRBPCR) was used.
Results and conclusions: Of the 276 patients enrolled, 215 (77.9%) were HIV positive. In HIV-
positive patients cryptococcal meningitis (CM) was the most common cause of meningitis (39.1%)
followed by pyogenic meningitis (PM) (30.7%), mononuclear meningitis (MM) (28.8%), and
tuberculous meningitis (TM) (1.4%). In HIV-negative patients, PM was the most common cause
(60.7%) followed by MM (37.7%) and CM (1.6%, one case). In-hospital mortality was higher in HIV-
positive patients (73/128 = 57%) compared to those HIV negative (3/18 = 16.7%) ( p = 0.001).
Streptococcus pneumoniae (n = 26) was the most common bacterial diagnosis, mainly in HIV-
positive patients (n = 22, 10.2%). Meningococcal meningitis (14 Neisseria meningitidis of group A
and one W135) was diagnosed in nine (4.2%) HIV-positive and six (9.8%) HIV-negative patients.
Gram-negative rods were isolated from five HIV-positive and two HIV-negative patients, respec-
tively. The bacteria and fungi involved in meningitis did not display high levels of in vitro* Corresponding author. Tel.: +33 1 44 38 95 76; fax: +33 1 45 68 89 53.
E-mail address: ygermani@pasteur.fr (Y. Germani).
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resistance. Conventional microbiology techniques failed to detect the causative agent in 55
(53.4%) PM cases. Broad-range bacterial PCR detected DNA from S. pneumoniae in three samples,
N. meningitidis in two, Escherichia coli in one, Listeria monocytogenes in two and Staphylococcus
aureus in one sample. In the CSF of five (three HIV negative and two HIV positive), PCR products
were not identified with the oligonucleotide probes specific for the usual species of bacteria
found in CSF, or genera commonly considered potential contaminants of clinical samples. Among
the MM cases, 77 (90.5%) probable viral meningitis (54 HIV positive and 23 HIV negative) and eight
TM (HIV positive) were suspected.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
The Central African Republic has been strongly affected by
the HIV epidemic.1 Highly active antiretroviral therapy
(HAART) is not easily available in this country. In Africa,
meningitis is among the most serious infections occurring
in individuals with HIV infection,2—7 and the HIV epidemic has
changed the pattern of meningitis in several countries.3—7
The causative organisms and the characteristics of adults
presenting with features of meningitis have not been studied
in the Central African Republic since 1994.8—10 In the Hoˆpital
Communautaire Medical Unit that serves as the referral
center for infectious diseases in adults in the Central African
Republic, meningitis represents nearly 20% of admissions.
Pyogenic meningitis constitutes 63% (593) of HIV-positive
cases and 66% (163) of HIV-negative cases. The goal of this
prospective study was to determine the causative organisms
and characteristics of HIV-positive and HIV-negative patients
presenting with features of meningitis in order to provide
guidance to physicians for case management.
Methods
Patients
The Hoˆpital Communautaire serves as the main primary
hospital for the 600 000 inhabitants of the capital city,
Bangui, and the surrounding areas. From April 1999 to Jan-
uary 2003, patients admitted to the Internal Medicine Ward
or to the Emergency Unit of this hospital with a clinical
suspicion of meningitis were systematically enrolled in the
study.
Meningitis was suspected in cases with meningeal symp-
toms (headaches, vomiting, neck rigidity, photophobia),
fever with altered mental status, unexplained changes in
mental status, fits or headache. Patients less than 18 years of
age and cases of cerebral malaria were excluded. The
patients or their next of kin gave informed consent. A ques-
tionnaire that included demographic characteristics, dura-
tion of illness, symptoms and signs on admission, alteration of
consciousness using the Glasgow Coma Scale (GCS), prior use
of antibacterial or antifungal drugs, and, in HIV-positive
patients, AIDS-defining illness and features of HIV infection,
was completed for each patient.11 Blood and CSF samples
were collected at the hospital. Empiric antibiotic treatment
according to WHO guidelines was begun immediately after
lumbar puncture: benzylpenicillin (12—24 million IU daily by
intravenous injection (IV)) or chloramphenicol (2—4 g daily IVfor a minimum of 7 days or for 4—5 days after the patient
became afebrile) in cases of bacteria and/or polynuclear
cells on CSF examination, and amphotericin B (0.5—0.7 mg/
kg daily by IV for six weeks), or alternatively fluconazole
(200—400 mg daily for 12 weeks), in cases of cryptococcal
meningitis.12 The study was interrupted for three months in
2000 and four months in 2002 because of military rebellions,
civil unrest, and a coup in Bangui. Only a small number of
patients treated for cryptococcal meningitis were followed
for six months.
Specimen collection and laboratory tests
Blood samples were obtained for full blood count, blood
smear for malaria parasites, and blood chemistry. All patients
were tested for HIV infection. They were considered to
have HIV infection if two ELISA tests (Genelavia Mixt,
Sanofi Pasteur and Vironostika, Organon) were positive.
CD4 T cell counts were performed by flow cytometry using
a Facs Calibur cytometer and Cell quest Software (Becton—
Dickinson).
CSF samples were submitted for routine microbiology,
chemistry (glucose, protein), and hematology testing. The
number of leukocytes was determined using a Nageotte
counting chamber. It was centrifuged and the supernatant
was used for the determination of protein and glucose
concentrations. The deposit was used for detection of anti-
gens to Neisseria meningitidis, Streptococcus pneumoniae,
Haemophilus influenzae (Slidex Me´ningite, kit 5 BioMe´rieux,
Marcy l’Etoile, France) and Cryptococcus neoformans poly-
saccharide antigen using a latex agglutination test (Pastorex
Plus, Biorad, Marnes la Coquette, France). The deposit was
used to prepare smears for Gram and Ziehl—Neelsen stains,
and India ink for microscopy. The deposit was also cultured
onto sheep blood, chocolate, bromocresol purple, and
Sabouraud plus chloramphenicol agar, and Lowenstein—Jen-
sen slope. Inoculatedmediawere incubated at 37 8C, and for
blood and chocolate agar in a CO2-enriched atmosphere jar.
Plateswere examined daily for up to 48 hours, and organisms
were identified using standard microbiology methods.13
Lowenstein—Jensen slopes were examined for up to six
weeks for growth of mycobacteria. Antimicrobial suscept-
ibility testing (disc diffusion methods, Sanofi Diagnostics
Pasteur) was only performed on bacterial and Cryptococcus
spp isolates.14,15
Two physicians and two microbiologists determined the
diagnostic category of meningitis according to the following
criteria: (i) pyogenic meningitis (PM) as pyogenic bacteria
detected on Gram stain, culture or positive antigen test in
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Table 1 Characteristics of studied populations and diag-
nostic categories of meningitis
HIV positive HIV negative
Number 215 (77.9%) 61 (22.1%)
Mean age (years) 26 49
Range 18—60 36—55
Sex ratio
(male/female)
1.12 1.13
CD4 cell count,
cells/mm3
(geometric mean)
160a 906b
Pyogenic
meningitis (PM)
66 (30.7%) 37 (60.7%)
Mononuclear
meningitis (MM)
62 (28.8%) 23 (37.7%)
Cryptococcal
meningitis (CM)
84 (39.1%) 1 (1.6%)
Tuberculous
meningitis (TM)
3 (1.4%) 0
a In HIV-positive patients CD4 lymphocyte counts were per-
formed in 33 CM, 46 PM, 62 MM and three TM cases with median
(range) counts of 16 (6—111) cells/mm3, 162 (26—338) cells/mm3,
68 (2—102) cells/mm3, and 85 (14—197) cells/mm3, respectively.
Between the different categories of meningitis in HIV-positive
patients, in CM there was a statistically significant difference
( p = 0.03) in the CD4 count. AIDS-related symptoms were
observed in all patients with CD4 cell counts <350 cells/mm3.
All patients presenting with meningitis were at the WHO clinical
stage C.
b In HIV-negative patients, CD4 lymphocyte counts were per-
formed in one CM, 16 PM and eight MMwithmedian (range) counts
of 1025 cells/mm3, 996 (886—1029) cells/mm3, and 832 (802—
996) cells/mm3, respectively.CSF, and/or total white cell count >5  106 cells/l (>50%
being polymorphonuclear cells); (ii) cryptococcal meningitis
(CM) as capsulate yeast cells detected in CSF by India ink
stain, positive culture for Cryptococcus spp or positive CSF
cryptococcal antigen test; (iii) tuberculous meningitis (TM) as
acid—alcohol fast bacilli detected on smears and/or myco-
bacteria grown on culture of CSF; (iv) mononuclear menin-
gitis (MM) as no bacteria or fungi on microscopy or culture of
CSF, and total white cell count >5  106 cells/l (>50% being
mononuclear cells).
Whenmicrobiological analyses were negative, the broad-
range bacterial polymerase chain reaction (BRBPCR) strat-
egy (a set of BRBPCR primers for the 16s rRNA gene in
bacteriawas used, alongwith three series of oligonucleotide
probes to detect the PCR product) developed by Greisen
et al.was used.16 The first series of probeswas broad in range
and consisted of a universal bacterial probe, aGram-positive
probe, a Bacteroides—Flavobacterium probe, and two
probes for other Gram-negative species. The second series
was designed to detect PCR products from seven major
bacterial species or groups frequently causing meningitis:
Neisseria meningitidis, Haemophilus influenzae, Strepto-
coccus pneumoniae, S. agalactiae, Escherichia coli and
other enteric bacteria, Listeria monocytogenes and Staphy-
lococcus aureus. The third series was designed for the
detection of DNA from species or genera commonly
considered potential contaminants of CSF: Bacillus, Cory-
nebacterium, Propionibacterium, and coagulase-negative
Staphylococcus spp.
Statistical analysis
Continuous variables were described with means and ranges.
Binary variables were expressed in percentages. The Chi-
square test (or Fisher’s exact test if necessary) was applied
for between-group comparisons. We used the Armitage trend
test for admission GCS scores. A p value <0.05 was consid-
ered statistically significant. The statistical analyses were
performed with Stata Software#, Version 8.0 (1999 Stata
Corp.).
Results
A total of 323 patients were included in the study. Of these,
47 (14.6%) were diagnosed as having conditions other than
meningitis after consideration of clinical presentation (three
septicemia, six malaria, nine unknown with no definitive
diagnosis at the time of discharge or death) and analysis of
CSF findings (28 hemorrhagic or without cells in CSF, one Loa
loa parasite).
Study population and clinical features
All subjects were heterosexual; none were intravenous drug
users or had received blood products. None were receiving
antiretroviral therapy during the study. The distribution of
patients according to their HIV serostatus and characteristics
of the studied populations are shown in Table 1. Of 276
patients with meningitis, 215 (77.9%) were HIV positive,
the proportion being above 64% in all types of meningitis,
with 98.8% and 100% seropositivity among cases with CM andTM, respectively. AIDS-related symptomswere observed in all
HIV-positive patients (score for AIDS (geometric mean): 8). In
199/215 patients the episode of meningitis was what first
brought to their attention their HIV-positive status. Mean age
differed significantly between HIV-positive and HIV-negative
groups ( p < 103) but sex distribution was not different. The
geometric mean CD4 cell counts were significantly lower in
the HIV-positive group ( p < 0.01).
Clinical characteristics are shown in Table 2. In-
hospital mortality was higher in HIV-positive patients (73/
128 = 57.0%) compared to those HIV negative (3/18 = 16.7%)
( p = 0.001), the proportion being above 75% in HIV-positive
patients with PM or CM, and lowest in MM (13%). In HIV-
negative patients mortality was only observed in PM (27%).
Most patients were admitted at a late stage of the illness.
Fever (temperature >38.5 8C) was more common in HIV-
positive patients with PM ( p < 0.001) and MM ( p = 0.001)
compared with CM. Headache was the most common and the
most prominent complaint in the various types of meningitis
in HIV-positive patients, and a more common symptom in
HIV-positive (93.9%) than in HIV-negative (78.6%) patients
( p = 0.02). In HIV-positive patients, neck stiffness was signi-
ficantly more commonly observed in PM than in CM
( p = 0.004). Seizure was more common in HIV-positive
patients with PM compared with MM ( p < 0.001), CM
( p < 0.001) and TM ( p = 0.007).
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Table 2 Clinical features of HIV-positive and HIV-negative patients with meningitis who presented at the Hoˆpital Communau ire of Bangui, the Central African Republic
HIV positive n = 215 HIV negative n = 61
Purulent
n = 66
Mononuclear
n = 62
Cryptococcal
n = 84
Tuberculous
n = 3
p Purulent
n = 37
Mo nuclear
n = 3
Cryptococcal
n = 1
Tuberculous
n = 0
p
In-hospital mortality
(% (total evaluated)) a
76 (49) 13 (46) 100 (30) 0 (3) <0.001 27 (11) 0 ) 0 (1) — 0.6
Symptomsb
(% (total evaluated)) a
Fever (>38.5 8C) 91.5 (47) 66.1 (59) 33.3 (39) 66.6 (3) <0.001 81 (16) 66. (9) 0 (1) — 0.21
Headache 96 (45) 90 (62) 100 (38) 66.6 (3) <0.05 72 (18) 88. (9) 100 (1) 0.71
Vomiting 33.3 (48) 37 (62) 27.7 (36) 33.3 (3) 0.84 38.8 (18) 22. (9) 0 (1) — 0.77
Photophobia 26.2 (42) 27.1 (59) 15.4 (39) 0 (3) 0.46 18.7 (16) 12. (8) 0 (1) — 1
Neck stiffness 46.3 (41) 30 (60) 15.8 (38) 0 (3) 0.02 37.5 (16) 11. (9) 0 (1) — 0.53
Seizures 84.7 (46) 23.3 (60) 15.8 (38) 0 (3) <0.001 17.6 (17) 16. (6) 0 (1) — 1
Antibiotics prior to admission
(% (total evaluated)) a
90.6 (43) 84.3 (51) 96.7 (31) 100 (3) 0.32 68.8 (16) 25 ) 100 (1) — 0.25
Past medical illness
(% (total evaluated))a, b
History of tuberculosis 0 (41) 21 (60) 19.4 (36) 100 (3) <0.001 0 (16) 0 ) 0 (1) — —
History of meningitis 0 (46) 0 (62) 0.3 (36) 0 (3) 0.27 0 (16) 0 ) 0 (1) — —
History of opportunistic infections
(in HIV positive)
45.2 (42) 21.7 (60) 91.7 (36) 100 (3) <0.001 0 (16) 0 ) 0 (1) — —
a The percentage of patients with a symptom or sign; the total number of individuals evaluated for the feature is given in parenthes .
b Only 16 HIV-positive patients (7.4%) and six HIV-negative patients (9.8%) presented to the hospital within 48 hours of the onset of t e symptoms.ta
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Table 3 Admission Glasgow Coma Scale (GCS) scores and mortality for 112 patients with meningitis
GCS scores Purulent meningitis Mononuclear meningitis Cryptococcal meningitis
Died n = 26 Survived n = 14 Died n = 6 Survived n = 39 Died n = 26 Survived n = 1
15 1 9 1 21 1 0
12—14 3 2 1 16 3 1
9—11 9 2 2 1 12 0
<9 13 1 2 1 10 0
Data are number of patients. Purulent meningitis, X2Armitage = 18.0, p < 0.001; mononuclear meningitis, X
2
Armitage = 13.3, p < 0.001;
cryptococcal meningitis, X2Armitage = 2.7, p = 0.1.Before admission, more HIV-positive patients (89.8%) than
HIV-negative patients (61.9%) had received some form of drug
treatment (p = 0.003). Overall, 66% of patients had received
various antibiotics (mainly trimethoprim—sulfamethoxazole)
before the CSF sample was submitted, but none according to
nationally accepted WHO guidelines. In HIV-positive patients,
a history of opportunistic infections was frequent (more fre-
quent in CM compared toMM (p < 0.001) and PM (p < 0.001)).
History of tuberculosis was frequent in TM and CM.
Admission GCS scores (Table 3) were available for 112
patients (40 PM, 45 MM and 27 CM) and were significantly
lower for patients who died (X2Armitage = 59.1, p < 0.001).
Forty-eight of 58 (82.8%) patients who died had a GCS score
below 12 (odds ratio (OR) = 47.0 [15.0—147.8]) against 9.3%
(5/54) of patients having survived (X2 = 60.6, p < 0.001). For
PM and MM patients, the lower the GCS score, the higher the
risk of death (in the case of a GCS score below 12, ORs were
20.2 [3.8—106.4] and 37.0 [4.0—338.9], respectively). No
significant trend appeared for CM patients (X2Armitage = 2.7,
p = 0.1).
Cerebrospinal fluid analysis
Table 4 shows microbial yields from CSF. In HIV-positive
patients, CM was the most common type of meningitisTable 4 Laboratory diagnosed meningitis in patients in relation
Etiologies of meningitis
Cryptococcal meningitis
Pyogenic meningitis
Streptococcus pneumoniae
Neisseria meningitidis
Gram-negative rodsc
Broad-range PCR strategyc
Probable bacterial meningitis d
Tuberculous meningitis
Mononuclear meningitis
Probable viral meningitis e
Probable tuberculous meningitis f
Data are number (%).
a Eight N. meningitidis of group A and one of group W135.
b Six N. meningitidis of group A.
c Details for the composition of these groups are given in the Result
d Leukocyte cell count >100  106 cells/l; differential cell count >50
e Leukocyte cell count <100  106 cells/l; differential cell count >5
f Leukocyte cell count >100  106 cells/l; differential cell count >6(39.1%), whereas it was PM in HIV-negative patients
(60.7%). Streptococcus pneumoniae (n = 26) was the most
common bacterial diagnosis, mainly in HIV-positive patients
(n = 22, 10.2%). It was cultured from the CSF of 18 patients,
identified solely on Gram stain of CSF in one, and on Gram
stain and detection of antigen in four. Only one (5.5%) of the
18 pneumococcal isolates was resistant to chloramphenicol.
Oxacillin disk sensitivity testing suggested the presence of
penicillin resistance in one (5.6%) strain. None of the N.
meningitidis isolates were resistant to chloramphenicol or
penicillin. In HIV-negative patients, the group of Gram-
negative rod isolates comprised Escherichia coli (one sam-
ple) andKlebsiella pneumoniae (one sample). InHIV-positive
patients it comprised Salmonella enterica typhimurium (one
sample), S. enterica enteritidis (one sample) and Entero-
bacter cloacae (one sample). Only theK. pneumoniae isolate
showed a reduced susceptibility to chloramphenicol. None
of the Gram-negative rod isolates was resistant to the
broad-spectrum cephalosporins. Mycobacterium tuberculo-
sis was isolated from only three patients, who responded
well to the usual chemotherapy recommended by the WHO
guidelines.12
Conventional microbiology techniques failed to detect the
etiology in 55 (53.4%) PM cases. From these probable bacter-
ial meningitis cases (all had the characteristics of PM: neu-
trophil predominance, high protein, low glucose, and into their HIV serostatus
HIV pos HIV neg
84 (39.1) 1 (0.16)
66 (30.7) 37 (60.7)
22 (10.2) 4 (6.6)
9a (4.2) 6b (9.8)
5 (2.3) 2 (3.3)
8 (3.7) 6 (9.8)
22 (10.2) 19 (31.1)
3 (1.4) 0 (0)
62 (28.8) 23 (37.7)
54 (25.1) 23 (37.7)
8 (3.7) 0
s section of the text.
% polymorphs; CSF protein >0.45 g/l; trace or absence of glucose.
0% lymphocytes; CSF proteins >0.45 g/l; normal glucose level.
5% lymphocytes; CSF protein >0.45 g/l; trace glucose.
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Table 5 Cerebrospinal fluid cell counts and biochemical parameters of patients with meningitis
Leukocyte count (109/l) Glucose (mmol/l) Protein (g/l)
Purulent meningitis
HIV pos (n = 6)a 1404 (33—10802) 0.3 (<0.1—12.3) 6.9 (3.2—11.2)
HIV neg (n = 33)a 1102 (83—9866) 0.32 (<0.1—15.8) 7.3 (4.4—10.8)
Mononuclear meningitis
HIV pos (n = 58)a 106 (62—430) 1.9 (0.9—11) 1.1 (0.3—1.9)
HIV neg (n = 19)a 208 (46—502) 3.5 (2—11.3) 1.9 (0.6—2.6)
Cryptococcal meningitis
HIV pos (n = 63)a 142 (31—1032) 1.6 (0.6—5.1) 1.8 (0.7—9.9)
HIV neg (n = 1) 4 1.4 0.37
Tuberculous meningitis
HIV pos (n = 3) 261 (70—470) 0.75 (0.36—1.2) 1.93 (1.9—2)
HIV neg (n = 0) — — —
Leukocyte counts, protein and glucose levels are means (ranges).
a Total number of individuals evaluated (results were not available for every patient).several cases there was a prompt response to antibacterial
drugs), a BRBPCR strategy detected DNA from S. pneumoniae
in three samples (two HIV-positive and one HIV-negative
patient), from N. meningitidis in two samples (one HIV-
positive and one HIV-negative patient), from E. coli in one
sample (HIV-positive patient), from Listeria monocytogenes
from two samples (one HIV-positive and one HIV-negative
patient) and from Staphylococcus aureus in one sample (HIV-
positive patient). In five CSF samples (three HIV-negative and
two HIV-positive patients), the PCR products were not iden-
tifiedwith the three series of oligonucleotide probes. In these
samples, bacterial meningitis was suspected because of the
leukocyte cell counts (>100  109 cells/l), differential cell
counts (>50% polymorphs), CSF protein (>0.45 g/l), and
glucose level (trace or absent). DNA of potentially contam-
inating bacteria was not detected in any of the tested
samples. Among PM cases, a total of 41 CSF (39.8%) remained
without etiology. These were categorized as probable bac-
terial meningitis because the clinical presentation was an
acute illness with at least two or more of the classic CSF
findings (neutrophil predominance, high protein, low glu-
cose) and several responded well to antibiotics.
Among the MM cases, a total of 77 (90.5%) with probable
viral meningitis (54 HIV positive, 23 HIV negative) were
suspected because of leukocyte cell counts (130 to
460  109 cells/l), differential cell counts (>50% lympho-
cytes), CSF protein (>0.45 g/l) and a normal glucose level.
A total of eight (9.4%) cases of probable tuberculous
meningitis, all from HIV-positive tuberculosis patients, were
suspected because of leukocyte cell counts (83 to 320 
109 cells/l), differential cell counts (>60% lymphocytes),
CSF protein (>0.45 g/l) and glucose level (trace or absent).
These patients had a previous history of tuberculosis.
Characteristics of CSF are shown in Table 5. There was no
significant difference in mean total CSF leukocyte count
(SD) or percentage of polymorphs in PM: (i) in CSF obtained
from HIV-positive ((1260  830)  109 cells/l; 78  42% poly-
morphs) or HIV-negative ((1130  380)  109 cells/l;
69  32% polymorphs; p = 0.3, Student’s t-test) patients;
(ii) in CSF obtained from patients with confirmed (microbio-logically or broad-range PCR) bacterial meningitis
((1680  892)  109 cells/l; 84  38% polymorphs) com-
pared with those with probable bacterial meningitis
((1464  328)  109 cells/l; 79  42% polymorphs; p = 0.2,
Student’s t-test). There was a wide range in MM and CM
results even though the average cell counts and biochemistry
fit the classic findings. A combination of normal CSF leuko-
cyte count (leukocytes 5  106 cells/l), glucose level
(2.2 mmol/l), and protein level (0.45 g/l) was found in
only three patients with CM.
Discussion
In Bangui, where 20% of the population of the Central African
Republic lives (i.e., approximately 600 000 inhabitants),
meningitis is a major component of opportunistic diseases
in HIV-positive adults and remains a frightening disease with
high morbidity and mortality in this developing country. The
Central African Republic ranks among the countries most
severely affected by HIV, and the increase in the cases of
meningitis seen since 1993 would appear to be a result of the
HIV epidemic.1,17,18 According to a previous study in the
Central African Republic,18 the majority (199/215) of HIV-
positive patients were not aware of their HIV status, pre-
senting de novo with an AIDS-defining illness in the form of
cryptococcal meningitis in 84/215 patients.
No reason was found for the much younger age of the HIV
group with meningitis. The clinical presentation in the var-
ious forms of meningitis in HIV-positive patients appears to
follow the known pattern of presentation in HIV-negative
patients. PM patients presented with fever, headache, sei-
zures and alteration in mental status. CM patients presented
mainly with headache. The main presenting feature of MM
patients was fever and headache. According to other studies
in Africa the CD4 lymphocyte counts clearly show a severe
degree of immunosuppression in the HIV-positive patients
with the four categories of meningitis.3,19—22
In this series of patients with meningitis who presented to
a government hospital in the Central African Republic, the
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favor of C. neoformans and S. pneumoniae. These findings
differ from those among HIV-positive patients with menin-
gitis in some South African countries where pneumococcal
meningitis is rare; this difference could result either from
local deployment of vaccines, from the availability of anti-
biotics, or from resistance to the antimicrobial drugs.21,22
Results in the Central African Republic reflect the findings of
most central and South African countries affected by
HIV.2,3,23—29
The bacteria and fungi involved in meningitis did not
display high levels of in vitro resistance to the antimicrobial
drugs commonly used to treat opportunistic infections in the
the Central African Republic. In spite of this, in HIV-positive
patients, the in-hospital mortality rates of PM and CM were
high, 76% and 100%, respectively. This high mortality rate
might be a reflection of late presentation of many of the HIV-
positive patients, as well as the use of inappropriate drugs by
most of these before their hospitalization. It is established
that delay in starting antimicrobial treatment has been
associated with both increased mortality and morbidity.23,25
As in other developing countries a very low percentage of
patients presented to hospital within 48 hours of the onset of
symptoms,23—25 whereas in developed countries the great
majority of patients present within 24 hours;27 this may be
one of the main determinants of the high mortality observed.
High in-hospital mortality rates have also been recorded for
the same reason in other settings with a high prevalence of
HIV infection3 — 53% in Tanzania,28 42% in South Africa,22 and
68% in Zimbabwe3. Furthermore, traditional healers are an
established part of society in the Central African Republic
and frequently provide the initial advice and treatment to
patients, especially those infected by HIV. This delay, and the
problem of poor transportation and lack of public awareness
in this disorganized country, may help to explain the delay in
presentation.
In the local community of Bangui, increasing public aware-
ness of the potential danger of meningitis could lower mor-
tality, especially in PM. In cases of bacterial meningitis, the
mortality was highest among those with a low GCS score.
Recognition of the significance of typical symptoms and of
altered consciousness could reduce delays in seeking treat-
ment and in turn reduce mortality.
The emergence of CM as an important opportunistic infec-
tion in HIV patients has been shown in many African stu-
dies.3—5,7,20—22 According to studies in other African
countries,3—5,7,20—22 in the Central African Republic, where
treatment is often unavailable, CM has an extremely poor
prognosis in HIV-positive patients (which is not the case in the
developed world).2 The duration of survival in our HIV-posi-
tive patients that were treated according to WHO guidelines
with appropriate anti-fungal agents, was better, but all
patients had died within six months.
The meningitis belt is now known to extend to all areas of
Africa where humidity is low for at least one month of the
year, and includes the Central African Republic. Several
reports from Africa have concluded that HIV infection does
not increase susceptibility to meningococcal disease.2,30 It is
the conclusion of this work as well. Although in the period of
this study outbreaks of meningitis attributable to N. menin-
gitidis were reported in the north of the Central African
Republic, we have been dealing with a high but steadyprevalence, suggesting an endemic rather than epidemic
situation in Bangui.
Surprisingly, a low prevalence of TM was observed. The
difficulties of laboratory diagnosis of tuberculous meningitis
have been well described, such that empirical chemother-
apy is justified for presumptive disease.25,31,32 M. tubercu-
losis was isolated from only three HIV-positive patients
(1.4%). It should be stressed that the diagnosis was pre-
sumptive in only eight HIV-positive patients, based on clin-
ical grounds and CSF findings. While there have been reports
of a high risk of tuberculous bacteremia in HIV-positive
patients and prediction of an anticipated overwhelming
increase in tuberculous meningitis in the Central African
Republic,33 this study does not substantiate this. A study of
1492 tuberculosis patients from Bangui showed that 2.7%
presented extrapulmonary tuberculosis.33 In the Central
African Republic, detection and treatment of tuberculosis
is a national priority and is free of charge. The disease
responds well to the usual chemotherapy including isonia-
zid, rifampin, ethambutol, and pyrazinamide for two
months, followed by isoniazid and ethambutol for another
six months.31 This could explain the low prevalence of TM in
the Central African Republic. Results of the application of
the PCR to the detection of M. tuberculosis have been
promising, and studies are in progress to investigate the
abnormal CSF.32,34
The inability to culture an agent from 55 (53.4%) pyogenic
meningitis cases is presumably due, at least in part, to the
use of antibiotic therapy prior to hospitalization. The poor
yield of Gram stain and culture, particularly in cases with
antibiotic treatment before hospital admission, has been
documented.2—6,22,25 A further contributory factor was prob-
ably the delay before laboratory investigations.
This study confirms the clinical utility of PCR for the
diagnosis of meningitis with use of a broad range of bacterial
primers.35 Faster accurate diagnosis of bacterial meningitis
would alleviate much of the worry associated with suspicion
of this disease, and also influence the initial empirical choice
of antimicrobial therapy. According to the pathogenic bac-
teria identified by using this tool, we conclude that the
antibiotics recommended in the WHO guidelines applied in
the Central African Republic would be efficient. Because the
sensitivity is not very high, presumably because we worked
under very stringent conditions, this BRBPCR of bacterial DNA
may augment but not replace culture as a detection method,
and, unfortunately, may not assist in the decision to discon-
tinue antibiotic therapy.
The meningitis probes used in this study identify most
causes of bacterial meningitis. For meningitis pathogens that
are not targeted with more specific probes, the broad-range
probes used here, were useful in five cases. This group of
organisms could include: (i) species that are known to cause
meningitis at a low frequency (such as P. aeruginosa, Legio-
nella species, and Enterococcus species) and (ii) novel spe-
cies that are not yet characterized. Bacteria in the latter
category may be undetectable by conventional culture meth-
ods because of fastidious growth characteristics or a low level
of bacteria in the sample. Further studies are in progress to
identify these organisms
The value of the BRBPCR for early detection of bacterial
meningitis has been demonstrated in several studies per-
formed in developed countries.35 In developing countries,
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reliability before it becomes a widely used test for the rapid
diagnosis of bacterial meningitis. The limitation to this
approach is that while several primers and oligonucleotide
probes are used to note the presence of specific pathogens,
the method remains expensive in poor countries such as the
Central African Republic and, in view of the lack of specific
information on antimicrobial susceptibility, the test would
not replace conventional culture and susceptibility testing.
Still today, in such a poor country, empirical chemotherapy
according to basic characteristics of CSF (Gram stain, cell
formula, glucose, protein) and following WHO guidelines is
justified for presumptive disease.
In conclusion, this study shows the serious problems posed
by the late presentation of patients with meningitis, and the
use of inappropriate drugs by most of them before their
hospitalization. CM and S. pneumoniae meningitis have
increased as a direct consequence of HIV infection in Bangui.
Because cryptococcal and bacterial infections have become
such important causes of meningitis, early appropriate diag-
nostic procedures, especially examination of CSF, are recom-
mended in patients presenting with headache. The use of
benzylpenicillin and chloramphenicol as recommended by
WHO guidelines should significantly influence the outcome
of patients with PM if given within 24 hours of the onset of
symptoms. The question of treatment of CM in the resource-
limited environment of the Central African Republic is an
issue that needs to be addressed.
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